FTC on First Amendment
This article was originally published in The Tan Sheet
Executive Summary
Consumers would benefit if FDA "expanded its use of regulatory approaches that allow the dissemination of truthful and non-misleading claims about the nutrient content and health benefits of foods," state 1FTC staff comments on FDA's application of the First Amendment. Commission staff suggest a "flexible approach" to commercial speech, rather than broad restrictions. "Advertising and labeling can be extremely effective tools to educate consumers about diet-disease relationships, to increase their awareness of diseases, to inform them of different treatment options and to empower them to manage better their own health," commission staff say. FTC's comments do not address the constitutionality of any specific FDA regulation or practice, or suggest revisions to its regulatory framework...
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.